This implies that passive immunization with tau antibodies is actually a practical therapeutic focus on and that the CSF amount of p-tau262/356 or in the microtubule binding area (MTBD) can serve as a valuable biomarker of tau pathology to monitor tau therapeutics in medical trials. Smart applian